This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John W. Newcomer, MD
Department of Psychiatry Washington University School of Medicine 4940 Children's Pl St Louis, MO 63110

William O. Faustman, PhD
Palo Alto, Calif

Robert B. Zipursky, MD
Toronto, Ontario

John G. Csernansky, MD
St Louis, Mo

Arch Gen Psychiatry. 1992;49(9):751-752.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Zacopride hydrochloride, a substituted benzamide, is a potent and selective antagonist at serotonin type 3 (5-HT₃) receptors^' that are found in brain areas receiving mesolimbic dopamine input.² Much interest has been generated by reports that direct infusion of zacopride and other 5-HT₃ antagonists into these mesolimbic areas in the rat inhibits dopaminergically mediated locomotor behavior without the overall depression of the central nervous system or rebound hyperlocomotion produced by conventional neuroleptic srugs.³ Zacopride has also been reported by some⁴ but not all⁵ investigators to have potent anxiolytic properties in animal models. Generally inactive at D₂ dopamine receptors⁶ and other neurotransmitter receptors,^7,8 this compound does not elevate plasma prolactin levels or cause catalepsy. Accordingly, zacopride has been hypothesized to have efficacy in the treatment of schizophrenia, without the side effects associated with conventional neuroleptic drugs. We sought to provide . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?